Government
Kaiser Health News recently published “Pharma Cash To Congress,” a campaign contributions tracker. KHN noted that, “Members of Congress raked in almost $4 million from the pharmaceutical manufacturers and their trade groups in the first six months of 2019.
Pharma stock prices took an across-the-board tumble Tuesday after Speaker of the House Nancy Pelosi unveiled a working plan to lower the prices of 250 of the most expensive drugs covered by Medicare and other government-funded programs.
The approval marks the first commercial product for Xeris.
The U.S. Food and Drug Administration (FDA) gave the thumbs-up to Boehringer Ingelheim’s Ofev (nintedanib) for systemic sclerosis-associated interstitial lung disease (SSc-ILD).
CDC Awarding Opioid Misuse Prevention Grants Directly to Local Health Departments for the First Time
The Centers for Disease Control and Prevention announced the recipients of its Overdose Data to Action grants, including those in 17 local jurisdictions.
$7.2 million total funding since 2015 for more providers of age-friendly healthcare
According to the U.S. Centers for Disease Control and Prevention, about 2 million people each year are infected with antibiotic-resistant bacteria and 23,000 people die as a result. A recent study by the UK government estimated that by 2050, as many as 10 million people could die worldwide from antibiotic-resistant infections.
Researchers from A*STAR’s Institute of Bioengineering and Nanotechnology have developed a customisable hydrogel that cultivates patient-derived tumour organoids which can better mimic the original.
In the first two weeks of September there were three scheduled PDUFA dates. One of those dates, for Celgene’s myelofibrosis drug, was approved early. Here’s a look.
The report, which is exaggerated or misinterpreted, appears to have been erroneous and triggered a short stock drop before the company and various analysts responded, calming investors.
PRESS RELEASES